Lanreotide Sun

Lanreotide, the active ingredient in Lanreotide Sun, is a somatostatin analog presented as a long‑acting injectable formulation for subcutaneous use. It is employed to control excess hormone production in conditions such as acromegaly and neuroendocrine tumors in adult patients.

GNH USA supplies Lanreotide Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, throughout. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution, including batch release certificates and stability data.

Lanreotide is a somatostatin analog used to manage hormone‑secreting tumors and related disorders. - Acromegaly: reduces excess growth hormone secretion and normalizes IGF‑1 levels. - Neuroendocrine tumors: controls tumor‑related hormone secretion and can inhibit tumor growth. - Carcinoid syndrome: alleviates flushing and diarrhea by suppressing serotonin release.

Lanreotide may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Injection site pain - Nausea - Diarrhea - Headache

Serious or Rare Side Effects: - Gallbladder disease (cholelithiasis) - Pancreatitis - Severe hyperglycemia or diabetic ketoacidosis - Allergic reactions, including anaphylaxis - Cardiac arrhythmias - Severe abdominal pain

When prescribing Lanreotide, several safety considerations should be observed. - Dose adjustment: renal or hepatic impairment may require closer monitoring. - Blood glucose monitoring: patients with diabetes may experience hyperglycemia. - Gallbladder monitoring: risk of gallstones; assess symptoms regularly. - Pregnancy: use only if potential benefit outweighs risk; safety not established. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Lanreotide can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - CYP450 inducers (e.g., rifampicin): may lower Lanreotide exposure. - Co‑administration with other somatostatin analogs (e.g., octreotide): additive hormonal suppression. - Antidiabetic agents: risk of severe hyperglycemia when combined. - Quinidine: may increase risk of QT‑interval prolongation.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR values. - Beta‑blockers: may mask hypoglycemia symptoms. - Diuretics: monitor electrolytes for potential imbalance.